vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与COMPASS MINERALS INTERNATIONAL INC（CMP）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是BIOCRYST PHARMACEUTICALS INC的2.5倍（$396.1M vs $156.4M），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs 7.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 4.3%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
BCRX vs CMP — 直观对比
营收规模更大
CMP
是对方的2.5倍
$156.4M
营收增速更快
CMP
高出21.5%
7.5%
两年增速更快
BCRX
近两年复合增速
4.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $396.1M |
| 净利润 | — | $18.6M |
| 毛利率 | — | 16.0% |
| 营业利润率 | 13.6% | 9.2% |
| 净利率 | — | 4.7% |
| 营收同比 | 7.5% | 28.9% |
| 净利润同比 | — | 178.8% |
| 每股收益（稀释后） | $0.00 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXCMP
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $396.1M | ||
| Q3 25 | $159.4M | $227.5M | ||
| Q2 25 | $163.4M | $214.6M | ||
| Q1 25 | $145.5M | $494.6M | ||
| Q4 24 | $131.5M | $307.2M | ||
| Q3 24 | $117.1M | $208.8M | ||
| Q2 24 | $109.3M | $202.9M |
净利润BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $18.6M | ||
| Q3 25 | $12.9M | $-7.2M | ||
| Q2 25 | $5.1M | $-17.0M | ||
| Q1 25 | $32.0K | $-32.0M | ||
| Q4 24 | $-26.8M | $-23.6M | ||
| Q3 24 | $-14.0M | $-48.3M | ||
| Q2 24 | $-12.7M | $-43.6M |
毛利率BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 16.0% | ||
| Q3 25 | 98.6% | 16.9% | ||
| Q2 25 | 98.3% | 19.2% | ||
| Q1 25 | 96.9% | 15.5% | ||
| Q4 24 | 95.4% | 11.2% | ||
| Q3 24 | 97.3% | 9.3% | ||
| Q2 24 | 98.4% | 16.1% |
营业利润率BCRXCMP
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 9.2% | ||
| Q3 25 | 18.6% | 5.3% | ||
| Q2 25 | 18.2% | 7.4% | ||
| Q1 25 | 14.6% | -0.6% | ||
| Q4 24 | -3.4% | 0.2% | ||
| Q3 24 | 6.6% | -14.3% | ||
| Q2 24 | 8.0% | 2.9% |
净利率BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 4.7% | ||
| Q3 25 | 8.1% | -3.2% | ||
| Q2 25 | 3.1% | -7.9% | ||
| Q1 25 | 0.0% | -6.5% | ||
| Q4 24 | -20.4% | -7.7% | ||
| Q3 24 | -12.0% | -23.1% | ||
| Q2 24 | -11.6% | -21.5% |
每股收益（稀释后）BCRXCMP
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.43 | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | $-0.41 | ||
| Q1 25 | $0.00 | $-0.77 | ||
| Q4 24 | $-0.13 | $-0.57 | ||
| Q3 24 | $-0.07 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $46.7M |
| 总债务越低越好 | — | $890.0M |
| 股东权益账面价值 | — | $260.5M |
| 总资产 | $465.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 3.42× |
8季度趋势，按日历期对齐
现金及短期投资BCRXCMP
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $46.7M | ||
| Q3 25 | $212.9M | $59.7M | ||
| Q2 25 | $260.0M | $79.4M | ||
| Q1 25 | $295.1M | $49.5M | ||
| Q4 24 | $320.9M | $45.8M | ||
| Q3 24 | $96.8M | $20.2M | ||
| Q2 24 | $78.4M | $12.8M |
总债务BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | — | $890.0M | ||
| Q3 25 | — | $839.8M | ||
| Q2 25 | — | $833.4M | ||
| Q1 25 | — | $807.6M | ||
| Q4 24 | — | $974.4M | ||
| Q3 24 | — | $921.2M | ||
| Q2 24 | — | $875.1M |
股东权益BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $260.5M | ||
| Q3 25 | $-387.9M | $234.1M | ||
| Q2 25 | $-421.6M | $249.8M | ||
| Q1 25 | $-451.9M | $236.5M | ||
| Q4 24 | $-475.9M | $263.0M | ||
| Q3 24 | $-468.6M | $316.6M | ||
| Q2 24 | $-475.6M | $352.1M |
总资产BCRXCMP
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.5B | ||
| Q3 25 | $446.4M | $1.5B | ||
| Q2 25 | $457.2M | $1.5B | ||
| Q1 25 | $480.0M | $1.5B | ||
| Q4 24 | $490.4M | $1.7B | ||
| Q3 24 | $491.3M | $1.6B | ||
| Q2 24 | $472.4M | $1.6B |
负债/权益比BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | 3.41× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 2.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-37.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-59.8M |
| 自由现金流率自由现金流/营收 | — | -15.1% |
| 资本支出强度资本支出/营收 | — | 5.8% |
| 现金转化率经营现金流/净利润 | — | -1.99× |
| 过去12个月自由现金流最近4个季度 | — | $94.1M |
8季度趋势，按日历期对齐
经营现金流BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $-37.0M | ||
| Q3 25 | $41.6M | $-6.9M | ||
| Q2 25 | $41.3M | $21.8M | ||
| Q1 25 | $-27.5M | $186.9M | ||
| Q4 24 | $-5.2M | $-4.1M | ||
| Q3 24 | $8.2M | $-12.7M | ||
| Q2 24 | $-1.4M | $-6.8M |
自由现金流BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $-59.8M | ||
| Q3 25 | $40.3M | $-22.8M | ||
| Q2 25 | $41.1M | $3.8M | ||
| Q1 25 | $-27.7M | $172.9M | ||
| Q4 24 | $-5.9M | $-25.9M | ||
| Q3 24 | $8.2M | $-33.6M | ||
| Q2 24 | $-1.5M | $-21.5M |
自由现金流率BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | -15.1% | ||
| Q3 25 | 25.3% | -10.0% | ||
| Q2 25 | 25.2% | 1.8% | ||
| Q1 25 | -19.0% | 35.0% | ||
| Q4 24 | -4.5% | -8.4% | ||
| Q3 24 | 7.0% | -16.1% | ||
| Q2 24 | -1.4% | -10.6% |
资本支出强度BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 5.8% | ||
| Q3 25 | 0.8% | 7.0% | ||
| Q2 25 | 0.1% | 8.4% | ||
| Q1 25 | 0.1% | 2.8% | ||
| Q4 24 | 0.5% | 7.1% | ||
| Q3 24 | 0.1% | 10.0% | ||
| Q2 24 | 0.1% | 7.2% |
现金转化率BCRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | -1.99× | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
